Fast-scan cyclic voltammetry to assess dopamine release in ex vivo mouse brain slices
By onThis protocol is to assess whether a drug changes the dopamine concentration released following a single pulse (1p) electrical stimulation.
Rethinking the network determinants of motor disability in Parkinson’s disease
By onFor roughly the last 30 years, the notion that striatal dopamine (DA) depletion was the critical determinant of network pathophysiology underlying the motor symptoms of Parkinson’s disease (PD) has dominated the field. While the basal ganglia circuit model underpinning this hypothesis has been of great heuristic value, the hypothesis itself has never been directly tested. Moreover, studies in the last couple of decades have made it clear that the network model underlying this hypothesis fails to incorporate key features of the basal ganglia, including the fact that DA acts throughout the basal ganglia, not just in the striatum. Underscoring this point, recent work using a progressive mouse model of PD has shown that striatal DA depletion alone is not sufficient to induce parkinsonism and that restoration of extra-striatal DA signaling attenuates parkinsonian motor deficits once they appear. Given the broad array of discoveries in the field, it is time for a new model of the network determinants of motor disability in PD.
A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis
By onThe gut and brain are interconnected in human disease. Colitis models show reproducible genetic programs affecting both colon and brain, highlighting immune activation and potential therapeutic targets in the gut-brain axis.
Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
By onStudies show nanoplastic pollution can trigger α-synuclein protein fibrils formation and spread in the brain, potentially linking nanoplastics to Parkinson's disease and related dementias.
The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner
By onAging is a neglected factor in neurodegeneration research. LRRK2 gene variations impact PD risk.R1441C mutation boosts immune response in young, but leads to immune exhaustion with age.Understanding LRRK2's immune effects is crucial for PD treatment.
Central and peripheral innate and adaptive immunity in Parkinson’s disease
By onParkinson’s disease is a chronic inflammatory disorder affecting multiple systems. Innovative immunomodulatory interventions are needed to address central and peripheral immune responses during disease onset and progression.
Calcium influx into astrocytes plays a pivotal role in inflammation-driven behaviors
By onSystemic inflammation can lead to astrogliosis, affecting neuronal activity linked to depressive behaviors. Orai1 calcium channel is crucial in this.Deleting Orai1 in astrocytes prevents astrogliosis, preserving normal neuronal activity and behavior.
CryoEM structure of amplified alpha-synuclein fibril class A type I with compact core from DLB case III
By onProtein fibril classification for Homo sapiens expressed in Escherichia coli 'BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structures of amplified alpha-synuclein fibril class A type I with extended core from DLB case I
By onProtein fibril classification for Homo sapiens expressed in Escherichia coli BL21(DE3) without mutations.
CryoEM structure of amplified alpha-synuclein fibril class A type I with extended core from DLB case X
By onProtein fibril classification for Homo sapiens, expressed in Escherichia coli strain BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structure of amplified alpha-synuclein fibril class A type I with extended core from DLB case VII
By onProtein fibril classification for Homo sapiens expressed in Escherichia coli 'BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structures of amplified alpha-synuclein fibril class B mixed type I/II with extended core from DLB case II
By onProtein fibril from Homo sapiens expressed in Escherichia coli strain BL21-Gold(DE3)pLysS AG with no mutations reported.
CryoEM structures of amplified alpha-synuclein fibril class B type II with extended core from DLB case I
By onProtein fibril classification in Homo sapiens expressed in Escherichia coli BL21(DE3) without mutations.
CryoEM structure of amplified alpha-synuclein fibril class B mixed type I/II with extended core from DLB case V
By onProtein fibril classification for Homo sapiens, expressed in Escherichia coli 'BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structures of amplified alpha-synuclein fibril class B type I with compact core from DLB case III
By onProtein fibril classification for Homo sapiens expressed in Escherichia coli 'BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structure of amplified alpha-synuclein fibril class B type I with extended core from DLB case VII
By onProtein fibril classification in Homo sapiens, expressed in Escherichia coli 'BL21-Gold(DE3)pLysS AG system without mutations.
Alpha-synuclein fibril from spontaneous control
By onProtein fibril from Homo sapiens expressed in Escherichia coli BL21-Gold(DE3)pLysS AG without mutations.
CryoEM structure of amplified alpha-synuclein fibril class B type I with extended core from DLB case X
By onProtein fibril classification for Homo sapiens using Escherichia coli 'BL21-Gold(DE3)pLysS AG expression system with no mutations identified.
CryoEM structure of amplified alpha-synuclein fibril class B type II with extended core from DLB case VII
By onProtein fibril from Homo sapiens expressed in Escherichia coli BL21-Gold(DE3)pLysS AG without mutations.
Boles_et-al_DSS_time-series
By onProcessed and normalized counts after the removal of low-quality genes and samples. These data are separated into colon ("colon_clean_VST_counts.csv") and brain ("brain_clean_VST_counts.csv").
